Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 601–700 of 15,747
Alsanafi, M., & Sallam, M. (2021) · Vaccines · doi:10.3390/vaccines9070701 · Cited by 165
“This might be related to the wide range of reports that have shown the superior efficacy of about 95%, compared to other currently available COVID-19 vaccines [6,14,62].”
ResultSkowronski, D. M., Febriani, Y., Ouakki, M., Setayeshgar, S., El Adam, S., Zou, M., Talbot, D., Prystajecky, N., Tyson, J. R., Gilca, R., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac290 · Cited by 155
“than 80% from 4 months to the end of follow-up [4, 5].”
Schmidt, T., Klemis, V., Schub, D., Schneitler, S., Reichert, M., Wilkens, H., Sester, U., Sester, M., & Mihm, J. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16818 · Cited by 157
Woolf, K., McManus, I. C., Martin, C., Nellums, L. B., Guyatt, A. L., Melbourne, C., Bryant, L., Gogoi, M., Wobi, F., Al‐Oraibi, A., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100180 · Cited by 185
“An unprecedented global research effort has resulted in effective vaccines against the causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1,2].”
Fix, O. K., Blumberg, E. A., Chang, K., Chu, J., Chung, R. T., Goacher, E. K., Hameed, B., Kaul, D. R., Kulik, L., Kwok, R. M., et al. (2021) · Hepatology · doi:10.1002/hep.31751 · Cited by 167
Real-time alerting system for COVID-19 and other stress events using wearable data
Alavi, A., Bogu, G. K., Wang, M., Rangan, E. S., Brooks, A. W., Wang, Q., Higgs, E., Celli, A., Mishra, T., Metwally, A. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01593-2 · Cited by 152
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy
Ramesh, S., Govindarajulu, M., Parise, R. S., Neel, L. T., Shankar, T., Patel, S., Lowery, P., Smith, F., Dhanasekaran, M., & Moore, T. (2021) · Vaccines · doi:10.3390/vaccines9101195 · Cited by 176
Ram, R., Hagin, D., Kikozashvili, N., Freund, T., Amit, O., On, Y. B., Beyar‐Katz, O., Shefer, G., Moshiashvili, M. M., Karni, C., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.024 · Cited by 149
“The mRNA SARS-CoV-2 vaccines were administered in the pivotal trials, and safety data have not raised any significant concerns [3, 9].”
BackgroundCOVIDSurg Collaborative, G. C. (2021) · British journal of surgery · doi:10.1093/bjs/znab101 · Cited by 203
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma
Perry, C., Luttwak, E., Balaban, R., Shefer, G., Morales, M., Aharon, A., Tabib, Y., Cohen, Y. C., Benyamini, N., Beyar‐Katz, O., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005094 · Cited by 153
Kumari, M., Lu, R., Li, M., Huang, J., Hsu, F., Ko, S.-H., Ke, F.-Y., Su, S.-C., Liang, K.-H., Yuan, J. P., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00852-9 · Cited by 178
“Brosh‑Nissimov T, Orenbuch‑Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID‑19 patients in Israel.”
BackgroundInfluentialANTi-Vax: a novel Twitter dataset for COVID-19 vaccine misinformation detection
Hayawi, K., Shahriar, S., Serhani, M. A., Taleb, I., & Mathew, S. S. (2021) · Public Health · doi:10.1016/j.puhe.2021.11.022 · Cited by 208
Lazarus, R., Baos, S., Cappel-Porter, H., Carson-Stevens, A., Clout, M., Culliford, L. A., Emmett, S. R., Garstang, J., Gbadamoshi, L., Hallis, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02329-1 · Cited by 168
“5,6 In a substudy of a phase 3 trial that assessed the safety and efficacy of a protein subunit COVID-19 vaccine with Matrix-M adjuvant (NVX-CoV 2373 ), cellular quadrivalent influenza vaccine was co-administered to participants aged 18–64 years with the first dose of the two dose COVID-19 vaccine…”
Approved Nanomedicine against Diseases
Jia, Y., Jiang, Y., He, Y., Zhang, W., Zou, J., Magar, K. T., Boucetta, H., Teng, C., & He, W. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030774 · Cited by 206
“Comirnaty® 2021 BNT162b2 Pfizer (New York, NY, USA) and BioNTech (Mainz, Germany) COVID-19 FDA intramuscular [113]”
Hall, V. G., Ferreira, V. H., Ierullo, M., Ku, T., Marinelli, T. M., Majchrzak-Kita, B., Yousuf, A., Kulasingam, V., Humar, A., & Kumar, D. (2021) · American Journal of Transplantation · doi:10.1111/ajt.16766 · Cited by 159
Toback, S., Galiza, E., Cosgrove, C. A., Galloway, J. B., Goodman, A. L., Swift, P. A., Rajaram, S., Graves-Jones, A., Edelman, J., Burns, F. M., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00409-4 · Cited by 163
COVID-19 and cellular senescence
Schmitt, C. A., Tchkonia, T., Niedernhofer, L. J., Robbins, P. D., Kirkland, J. L., & Lee, S. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00785-2 · Cited by 153
SARS‐CoV‐2 re‐infection risk in Austria
Pilz, S., Chakeri, A., Ioannidis, J. P., Richter, L., Theiler‐Schwetz, V., Trummer, C., Krause, R., & Allerberger, F. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13520 · Cited by 152
Rzymski, P., Borkowski, L., Drąg, M., Flisiak, R., Jemielity, J., Krajewski, J., Mastalerz–Migas, A., Matyja, A., Pyrć, K., Simon, K. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9020109 · Cited by 172
Extended interval BNT162b2 vaccination enhances peak antibody generation
Parry, H., Bruton, R., Stephens, C., Bentley, C., Brown, K., Amirthalingam, G., Hallis, B., Otter, A., Zuo, J., & Moss, P. (2022) · npj Vaccines · doi:10.1038/s41541-022-00432-w · Cited by 150
Korth, J., Jahn, M., Dorsch, O., Anastasiou, O. E., Sorge-Hädicke, B., Eisenberger, U., Gäckler, A., Dittmer, U., Witzke, O., Wilde, B., et al. (2021) · Viruses · doi:10.3390/v13050756 · Cited by 155
“Twenty-three renal transplant recipients of the Nierenzentrum Kronach, Germany were intramuscularly vaccinated twice with a gap of 22.0 +/− 4.6 days between the shots with the mRNA-based SARS-CoV-2 vaccine BNT162b2 (Pfizer-BioNTech) according to the standard protocol at a vaccination center in Kronach, Germany [9].”
MethodInfluentialDilliard, S. A., Sun, Y., Brown, M. O., Sung, Y., Chatterjee, S., Farbiak, L., Vaidya, A., Lian, X., Wang, X., Lemoff, A. S., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.058 · Cited by 167
SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis
Velikova, T. V., & Georgiev, T. (2021) · Rheumatology International · doi:10.1007/s00296-021-04792-9 · Cited by 162
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
Risma, K., Edwards, K. M., Hummell, D. S., Little, F. F., Norton, A. E., Stallings, A. P., Wood, R. A., & Milner, J. D. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.04.002 · Cited by 162
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac933 · Cited by 155
Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Hasan, M. R., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2209306 · Cited by 148
Current and innovative methods for the diagnosis of COVID‑19 infection (Review)
Falzone, L., Gattuso, G., Tsatsakis, A. M., Spandidos, D. A., & Libra, M. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.4933 · Cited by 183
Tortorella, C., Aiello, A., Gasperini, C., Agrati, C., Castilletti, C., Ruggieri, S., Meschi, S., Matusali, G., Colavita, F., Farroni, C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000013108 · Cited by 165
Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines
Doroftei, B., Ciobica, A. S., Ilie, O., Maftei, R., & Ilea, C. G. (2021) · Diagnostics · doi:10.3390/diagnostics11040579 · Cited by 164
Duléry, R., Lamure, S., Delord, M., Blasi, R. D., Chauchet, A., Hueso, T., Rossi, C., Drénou, B., Deau, B., Soussain, C., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26209 · Cited by 155
Tenforde, M. W., Patel, M. M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Gaglani, M., McNeal, T., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab687 · Cited by 149
“We conducted a prospective observational case-control evaluation of vaccine effectiveness by comparing the odds of antecedent SARS-CoV-2 vaccination in hospitalized case-patients with Covid19 versus control-patients without Covid-19.”
BackgroundResultInfluentialCOVID ‐19: immunopathology, pathophysiological mechanisms, and treatment options
van Eijk, L. E., Binkhorst, M., Bourgonje, A. R., Offringa, A. K., Mulder, D. J., Bos, E. M., Kolundžić, N., Abdulle, A. E., van der Voort, P. H. J., Rikkert, M. G. M. O., et al. (2021) · The Journal of Pathology · doi:10.1002/path.5642 · Cited by 172
Safety of SARS-CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled trials
Chen, M., Yuan, Y., Zhou, Y., Deng, Z., Zhao, J., Feng, F., Zou, H., & Sun, C. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00878-5 · Cited by 157
“Very few cases of Bell’s palsy following vaccination were reported in clinical trials on both the Pfizer-BioNTech vaccines and Moderna vaccines [16, 19].”
BackgroundInfluentialGoshen-Lago, T., Waldhorn, I., Holland, R., Szwarcwort-Cohen, M., Reiner-Benaim, A., Shachor-Meyouhas, Y., Hussein, K., Fahoum, L., Baruch, M., Peer, A., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2675 · Cited by 147
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
Roeker, L. E., Knorr, D. A., Thompson, M. C., Nivar, M., Lebowitz, S., Peters, N., Deonarine, I., Momotaj, S., Sharan, S., Chanlatte, V., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01270-w · Cited by 150
“While randomized controlled trials demonstrated 94–95% efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike messenger RNA (mRNA) vaccines [1, 2], efficacy in immunocompromised patients has not been established.”
Izmirly, P., Kim, M., Samanovic, M. I., Fernandez‐Ruiz, R., Ohana, S., Deonaraine, K., Engel, A., Masson, M., Xie, X., Cornelius, A. R., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41937 · Cited by 163
Jyssum, I., Kared, H., Tran, T. T., Tveter, A. T., Provan, S. A., Sexton, J., Jørgensen, K. K., Jahnsen, J., Kro, G. B., Warren, D. J., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00394-5 · Cited by 160
Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2
Dangi, T., Class, J., Palacio, N. M., Richner, J. M., & Penaloza‐MacMaster, P. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109664 · Cited by 147
mRNA vaccine in cancer therapy: Current advance and future outlook
Li, Y., Wang, M., Peng, X., Yang, Y., Chen, Q., Liu, J., She, Q., Tan, J., Lou, C., Liao, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1384 · Cited by 176
Nordström, P., Ballin, M., & Nordström, A. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100249 · Cited by 144
“Cumulative incidence and 95% confidence intervals for symptomatic Covid-19 infecti homologous BNT162b2 prime-boost vaccination had a 95% efficacy against laboratory confirmed Covid-19 [3].”
BackgroundCOVID-19 in dialysis: clinical impact, immune response, prevention, and treatment
Karoui, K. E., & Vriese, A. S. D. (2022) · Kidney International · doi:10.1016/j.kint.2022.01.022 · Cited by 157
A comprehensive analysis of the efficacy and safety of COVID-19 vaccines
Cai, C., Peng, Y., Shen, E., Huang, Q., Chen, Y., Liu, P., Guo, C., Feng, Z., Gao, L., Zhang, X., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.001 · Cited by 146
Kadali, R. A. K., Janagama, R., Peruru, S., Gajula, V., Madathala, R. R., Chennaiahgari, N., & Malayala, S. V. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26996 · Cited by 156
Sauré, D., O’Ryan, M., Torres, J. P., Zuniga, M., Santelices, E., & Basso, L. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00479-5 · Cited by 175
Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models
Dey, A., Rajanathan, T. M. C., Chandra, H., Pericherla, H. P. R., Mendiratta, S. K., Choonia, H. S., Bajpai, M., Singh, A. K., Sinha, A., Saini, G., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.098 · Cited by 156
Species-dependent in vivo mRNA delivery and cellular responses to nanoparticles
Hatit, M. Z. C., Lokugamage, M. P., Dobrowolski, C. N., Paunovska, K., Ni, H., Zhao, K., Vanover, D., Beyersdorf, J., Peck, H. E., Loughrey, D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-021-01030-y · Cited by 145
Fadlyana, E., Rusmil, K., Tarigan, R., Rahmadi, A. R., Prodjosoewojo, S., Sofiatin, Y., Khrisna, C. V., Sari, R. M., Setyaningsih, L., Surachman, F., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.09.052 · Cited by 156
Bartsch, Y. C., Tong, X., Kang, J., Avendaño, M. J., Serrano, E. F., García‐Salum, T., Pardo‐Roa, C., Riquelme, A. J., Cai, Y., Renzi, I., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9243 · Cited by 146
COVID-19 Vaccines and the Skin
Sun, Q., Fathy, R. A., McMahon, D. E., & Freeman, E. E. (2021) · Dermatologic Clinics · doi:10.1016/j.det.2021.05.016 · Cited by 156
The use of RNA-based treatments in the field of cancer immunotherapy
Chehelgerdi, M., & Chehelgerdi, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01807-w · Cited by 168
COVID‐19 vaccinations: The unknowns, challenges, and hopes
Mohamed, K., Rzymski, P., Islam, M. S., Makuku, R., Mushtaq, A., Khan, A., Ivanovska, M., Makka, S. A., Hashem, F., Marquez, L. P., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27487 · Cited by 170
“In December 2020, the clinical trial with the BNT162b2 vaccine showed 95% protection against infection, and safety was surveilled over two months with similar results to other viral vaccines.(31) This first trial”
BackgroundResultInfluentialExosome for mRNA delivery: Strategies and therapeutic applications
Iqbal, Z., Rehman, K., Mahmood, A., Shabbir, M., Liang, Y., Duan, L., & Zeng, H. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02634-x · Cited by 144
“Recently, two mRNA vaccines targeting severe acute respiratory coronavirus type 2 (SARS-CoV-2) were licensed to prevent COVID-19 infection [3–6].”
BackgroundThe emerging plasticity of SARS-CoV-2
McCormick, K. D., Jacobs, J. L., & Mellors, J. W. (2021) · Science · doi:10.1126/science.abg4493 · Cited by 140
Lustig, Y., Zuckerman, N., Nemet, I., Atari, N., Kliker, L., Regev-Yochay, G., Sapir, E., Mor, O., Alroy-Preis, S., Mendelson, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100557 · Cited by 141
Chatzikleanthous, D., O’Hagan, D. T., & Adamo, R. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00447 · Cited by 144
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · doi:10.1101/2022.02.25.22271494 · Cited by 143
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 166
Groß, R. M., Zanoni, M., Seidel, A., Conzelmann, C., Gilg, A., Krnavek, D., Erdemci-Evin, S., Mayer, B., Hoffmann, M., Pöhlmann, S., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103761 · Cited by 145
“The BNT162b2 encoded spike sequence contains a two-proline mutation not present in ChAdOx1 nCoV-19, which fix spike in a pre-fusion confirmation (10, 34).”
Srivastava, K., Carreño, J. M., Gleason, C., Monahan, B., Singh, G., Abbad, A., Tcheou, J., Raskin, A. J., Kleiner, G., van Bakel, H., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.017 · Cited by 178
da Silva, J. R., Rodrigues, K. B., Pelegrin, G. F., Sales, N. S., Muramatsu, H., Silva, M. D. O., Porchia, B. F. M. M., Moreno, A. C. R., Aps, L. R. M. M., Venceslau-Carvalho, A. A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abn3464 · Cited by 165
Terpos, E., Trougakos, I. P., Apostolakou, F., Charitaki, I., Sklirou, A. D., Mavrianou, N., Papanagnou, E., Liacos, C., Gumeni, S., Rentziou, G., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26185 · Cited by 143
“(Comirnaty) is the first approved by both FDA and EMA, due to its efficacy in apparently healthy adults.(2) Recently, an assessment of the first vaccination dose effects among nursing facility residents and staff showed that there is some protection after the first injection.”
BackgroundNeutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
Xie, X., Zou, J., Fontes-Garfias, C. R., Xia, H., Swanson, K. A., Cutler, M., Cooper, D., Menachery, V. D., Weaver, S., Dormitzer, P. R., et al. (2021) · doi:10.1101/2021.01.07.425740 · Cited by 143
Self-citationCytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy
Jiang, Y.-Z., Rubin, L., Peng, T., Liu, L., Xing, X., Lazarovici, P., & Zheng, W. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59272 · Cited by 163
“% efficacy in disease prevention and a good safety profile in adults patients [132] and adolescents [133].”
BackgroundAu, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143
Machtakova, M., Thérien‐Aubin, H., & Landfester, K. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00686j · Cited by 159
Hassan, A. O., Feldmann, F., Zhao, H., Curiel, D. T., Okumura, A., Tang-Huau, T.-L., Case, J. B., Meade-White, K. D., Callison, J. A., Chen, R. E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100230 · Cited by 144
Nanotechnology-based strategies against SARS-CoV-2 variants
Huang, X., Kon, E., Han, X., Zhang, X., Kong, N., Mitchell, M. J., Peer, D., & Tao, W. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01174-5 · Cited by 155
Ben‐Akiva, E., Karlsson, J. E., Hemmati, S., Yu, H., Tzeng, S. Y., Pardoll, D. M., & Green, J. J. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2301606120 · Cited by 154
“The use of lipid nanoparticles (LNPs) for delivery of mRNA encoding the spike protein of the SARS- CoV-2 virus has provided safe and powerful vaccine technologies against COVID-19 (7–9), demonstrating the great potential and increasing public acceptance of mRNA vaccines.”
BackgroundTartof, S. Y., Slezak, J. M., Puzniak, L., Hong, V., Xie, F., Ackerson, B. K., Valluri, S. R., Jodar, L., & McLaughlin, J. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00101-1 · Cited by 140
Immune response to SARS-CoV-2 variants of concern in vaccinated individuals
Becker, M., Dulovic, A., Junker, D., Ruetalo, N., Kaiser, P. D., Pinilla, Y. T., Heinzel, C., Haering, J., Traenkle, B., Wagner, T. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23473-6 · Cited by 138
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Tsai, S. J., Atai, N. A., Cacciottolo, M., Nice, J., Salehi, A., Guo, C., Sedgwick, A., Kanagavelu, S., & Gould, S. J. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101266 · Cited by 142
Antibody Responses in COVID-19: A Review
Chvatal‐Medina, M., Cortina, Y. A. M., Grajales, P. J. P., Velilla, P. A., & Rugeles, M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633184 · Cited by 162
Terpos, E., Trougakos, I. P., Gavriatopoulou, M., Papassotiriou, I., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Papanagnou, E., Fotiou, D., Kastritis, E., & Dimopoulos, M. A. (2021) · Blood · doi:10.1182/blood.2021011904 · Cited by 137
Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141
CARBON DOTS: Bioimaging and Anticancer Drug Delivery
Bartkowski, M., Zhou, Y., Mustafa, M. N. A., Eustace, A. J., & Giordani, S. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202303982 · Cited by 156
Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains
Rella, S. A., Kulikova, Y. A., Dermitzakis, E. T., & Kondrashov, F. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-95025-3 · Cited by 146
Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine
Carli, G., Nichele, I., Ruggeri, M., Barra, S., & Tosetto, A. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02685-0 · Cited by 156
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment
Li, D., Sempowski, G. D., Saunders, K. O., Acharya, P., & Haynes, B. F. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-113838 · Cited by 138
Smadja, D. M., Yue, Q., Chocron, R., Sanchez, O., & Louët, A. L. (2021) · European Respiratory Journal · doi:10.1183/13993003.00956-2021 · Cited by 149
“after injection of three anti-COVID-19 vaccines (Comirnaty® from Pfizer-BioNtech; COVID-19 vaccine Moderna and AZD1222 from Astra Zeneca) (7-9) until March 16, 2021.”
MethodInvestigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination
Lee, K. M. N., Junkins, E. J., Luo, C., Fatima, U. A., Cox, M. L., & Clancy, K. B. H. (2022) · Science Advances · doi:10.1126/sciadv.abm7201 · Cited by 148
“, solicited local and systemic adverse events) in vaccine trials [see (40, 41)].”
BackgroundPrabhu, M., Murphy, E. A., Sukhu, A. C., Yee, J. K., Singh, S., Eng, D., Zhao, Z., Riley, L. E., & Yang, Y. J. (2021) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000004438 · Cited by 158
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 158
Naranbhai, V., García-Beltrán, W. F., Chang, C. C., Berrios, C., Thierauf, J., Kirkpatrick, G., Onozato, M. L., Cheng, J., Denis, K. S., Lam, E. C., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab593 · Cited by 152
“Vaccination with mRNA-1273[1](100ug, Moderna), BNT162b2[2](30ug, Pfizer) and Ad26.”
Rief, W. (2021) · JAMA Health Forum · doi:10.1001/jamahealthforum.2021.0804 · Cited by 137
Mazzoni, A., Di Lauria, N., Maggi, L., Salvati, L., Vanni, A., Capone, M., Lamacchia, G., Mantengoli, E., Spinicci, M., Zammarchi, L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149150 · Cited by 139
“Approved COVID-19 mRNA vaccines require a first dose followed 3 to 4 weeks later by a second injection (6, 7).”
BackgroundResultLuxi, N., Giovanazzi, A., Capuano, A., Crisafulli, S., Cutroneo, P. M., Fantini, M. P., Ferrajolo, C., Moretti, U., Poluzzi, E., Raschi, E., et al. (2021) · Drug Safety · doi:10.1007/s40264-021-01131-6 · Cited by 159
Bayart, J., Douxfils, J., Gillot, C., David, C., Mullier, F., Elsen, M., Eucher, C., Eeckhoudt, S. V., Roy, T., Gérin, V., et al. (2021) · Vaccines · doi:10.3390/vaccines9101092 · Cited by 138
“The efficacy and safety of the two-dose regimen of BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech, Mainz, Germany) have been proven and led to an emergency use authorization (EUA) delivered on the 11th of December 2020 [1].”
Background2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma
(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 150
Lai, F. T. T., Li, X., Peng, K., Huang, L., Ip, P., Tong, X., Chui, C. S. L., Wan, E. Y. F., Wong, C. K. H., Chan, E. W., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-3700 · Cited by 152
COVID ‐19 Vaccine‐Associated Cerebral Venous Thrombosis in Germany
Schulz, J. B., Berlit, P., Diener, H., Gerloff, C. P., Greinacher, A., Klein, C., Petzold, G. C., Piccininni, M., Poli, S., Röhrig, R., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26172 · Cited by 170
Neutralising antibodies predict protection from severe COVID-19
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S., & Davenport, M. P. (2022) · doi:10.1101/2022.06.09.22275942 · Cited by 139
BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers
Benenson, S., Oster, Y., Cohen, M. J., & Nir‐Paz, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2101951 · Cited by 142
Xue, L., Hamilton, A. G., Zhao, G., Xiao, Z., El-Mayta, R., Han, X., Gong, N., Xiong, X., Xu, J., Figueroa-Espada, C. G., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45422-9 · Cited by 137
Efficacy and safety of COVID-19 vaccines: a systematic review.
Xing, K., Tu, X.-Y., Liu, M., Liang, Z.-W., Chen, J.-N., Li, J. J., Jiang, L.-G., Xing, F.-Q., & Jiang, Y. (2021) · PubMed Central · doi:10.7499/j.issn.1008-8830.2101133 · Cited by 148
Jabagi, M. J., Botton, J., Bertrand, M., Weill, A., Farrington, P., Zureik, M., & Dray-Spira, R. (2022) · JAMA · doi:10.1001/jama.2021.21699 · Cited by 137
Agrawal, U., Katikireddi, S. V., McCowan, C., Mulholland, R. H., Azcoaga-Lorenzo, A., Amele, S., Fagbamigbe, A. F., Vasileiou, E., Grange, Z., Shi, T., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00380-5 · Cited by 153
“7,14,15 However, these studies might not necessarily reflect real-world outcomes because of exclusion or under-representation of certain populations (such as older age groups and those with comorbidities), differences in risk of infection during the observation periods, different criteria for…”
COVID-19: Rethinking the Lockdown Groupthink
Joffe, A. R. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.625778 · Cited by 183
COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials
Desai, A. P., Gainor, J. F., Hegde, A. M., Schram, A. M., Curigliano, G., Pal, S. K., Liu, S. V., Halmos, B., Groisberg, R., Grande, E., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00487-z · Cited by 147
Kageyama, T., Ikeda, K., Tanaka, S., Taniguchi, T., Igari, H., Onouchi, Y., Kaneda, A., Matsushita, K., Hanaoka, H., Nakada, T., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.042 · Cited by 149
“BNT162b2 mRNA vaccine against COVID-19 has shown promising efficacy both in a clinical trial [1] and in nationwide mass vaccination settings [2].”
Background
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.